Prostate Cancer Zytiga

TREATING PROSTATE CANCER WITH ZYTIGA What Is ZYTIGA? How Does ...
TREATING PROSTATE CANCER WITH ZYTIGA Remember your regular check-ups whilst taking ZYTIGA Your doctor will meet with you before starting ZYTIGA. ... Get Document

Zytiga, INN-abiraterone Acetate
Zytiga is used to treat cancer of the prostate (a gland of the male reproductive system) in adult men The full EPAR for Zytiga can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. ... Access Document

For The Treatment Of Metastatic Castration-Resistant Prostate ...
For the Treatment of Metastatic Castration-Resistant Prostate Cancer Value Story Second Release 21 May 2015 STRICTLY CONFIDENTIAL For internal use only ... View This Document

PRIOR AUTHORIZATION CRITERIA FOR ZYTIGA (ABIRATERONE ACETATE ...
Zytiga (abiraterone acetate) and Xtandi (enzalutamide)Prior Authorization, UMC 530-0121 Xtandi is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-resistant ... Retrieve Here

Zytiga™ (abiraterone Acetate)
Zytiga™ (abiraterone acetate) (Oral) Document Number: IC-0155 Last Review Date: 06/24/2014 Date of Origin: 11/06/2012 Prostate Cancer† • Patient Age 18 years and older; AND • Patient’s disease is metastatic AND castration-resistant; AND ... Access Content

BCCA Protocol Summary For Palliative Therapy For Metastatic ...
BCCA Protocol Summary for Palliative Therapy for Metastatic Castration Resistant Prostate Cancer Using Abiraterone and Prednisone . Protocol Code: ... Access Full Source

Top 20 Cancer Drugs - Page 2 - Pharma At About.com
11. Zytiga Manufacturer: Johnson & Johnson. Condition or Diseases treated: Prostate cancer. Global 2013 sales: $1.7 billion. Generic name: Abiraterone acetate ... Read Article

Zytiga (abiraterone) Prior Approval Criteria
Zytiga (abiraterone) Prior Approval Criteria September 2014 Definition: Prostate cancer that is sensitive to androgen responds to treatment that decreases androgen levels. Gonadotropin releasing hormone (GnRH) agonists or ... Read More

Starting Treatment Early For Metastatic Prostate Cancer: Part III
Doctors use excessively conservative thinking for many reasons and don't always evaluate “outside the box,” treatment approaches. ... Read Article

Zytiga® (abiraterone)
Metastatic Castration-Resistant Prostate Cancer? Zytiga® (abiraterone) Created Date: 6/18/2013 2:26:48 PM ... Read More

HIGHLIGHTS OF PRESCRIBING INFORMATION ...
HIGHLIGHTS OF PRESCRIBING INFORMATION ZYTIGA is a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer . (1) ... Access Document

MEDICARE PART D COVERAGE CRITERIA ZYTIGA (abiraterone)
All FDA-approved indications not otherwise excluded from Part D . Coverage Criteria: ***PA criteria apply to new-start therapy only*** 1) Metastatic Prostate Cancer: ... Access Doc

zytiga - Pa - HMSA
Zytiga Other _____ 2. What is the diagnosis? Metastatic prostate cancer Other _____ 3. What is the ICD code? _____ 4. Is Zytiga used in combination with prednisone? Yes No ** Please attach most recent clinical ... Get Doc

Dr. Mary-Ellen Taplin On Abiraterone Acetate's Mechanism Of ...
Mary-Ellen Taplin, MD, associate professor of Medicine at Harvard Medical School and the Dana-Farber Cancer Institute, describes the mechanism of action for the oral androgen biosynthesis inhibitor abiraterone acetate (Zytiga), which is approved for treating men with castration ... View Video

Zytiga Prior Authorization Form - Priority Health
Zytiga ® (abiraterone) metastatic castration-resistant prostate cancer Other – the patient’s condition is: B. What is the patient’s ECOG status? 0: Fully active, able to carry on all pre-disease performance without restriction ... Fetch Document

COU-AA-302 Data Summary And Perspectives On ZYTIGA ...
COU-AA-302 Data Summary and Perspectives on ZYTIGA Metastatic Castration-resistant Prostate Cancer (mCRPC) CJ Ryan,1 MR Smith,2 JS de Bono,3 A Molina,4 C Logothetis,5 P De Souza,6 K Fizazi,7 P Mainwaring,8 JR Piulats,9 S Ng,10 J Carles,11 PFA Mulders,12 T ... Retrieve Here

Zytiga, INN-abiraterone Acetate
Zytiga (abiraterone) Procedure no. EMEA/H/C/002321/II/0004/G . Note . Variation assessment report as adopted by the CHMP with all information of a commercially in patients with prostate cancer. Nevertheless, as abiraterone increased OS in the post-docetaxel stage ... Access Document

PROSTATE CANCER TREATMENT REGIMENS
PROSTATE CANCER TREATMENT REGIMENS The selection, dosing, and administration of anticancer agents and the management of associated toxicities are complex. ... Retrieve Doc

Prostate Cancer Studies - Urology Cancer Center
Prostate Cancer Studies Cougar 301 - Zytiga™ Phase III study of oral Zytiga™ plus prednisone for patients with advanced prostate cancer who have already received chemotherapy Closed to enrollment ... Read Full Source

Brand Name: Zytiga - WVU Pharmacy
Brand Name: Zytiga Generic Name: abiraterone acetate Manufacturer1: Antiandrogen Uses: Labeled1,2,3,4: Metastatic castration-resistant prostate cancer (in combination with prednisone) in patients who have received prior chemotherapy containing docetaxel Unlabeled: none ... Document Viewer

Pharmacy Medical Necessity Guidelines: Zytiga® (abiraterone)
Zytiga (abiraterone) in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). PHARMACY COVERAGE GUIDELINES Tufts Health Plan may authorize coverage of Zytiga ... Return Doc

Prostate Cancer Studies - Gucancer.com
Prostate Cancer Studies Cougar 301 - Zytiga™ Phase III study of oral Zytiga™ plus prednisone for patients with advanced prostate cancer who have already received chemotherapy Closed to enrollment ... Access This Document

Prior Authorization Request - Zytiga
1. What drug is being prescribed? Zytiga® Other 2. What is the patient's diagnosis? Prostate cancer _____ ... Content Retrieval

Abiraterone Acetate - Wikipedia, The Free Encyclopedia
Abiraterone acetate (INN, USAN, BAN, JAN) (brand names Zytiga, Abiratas, Abretone, Abirapro) is a steroidal antiandrogen, specifically an androgen synthesis inhibitor, used in combination with prednisone in metastatic castration-resistant prostate cancer (formerly hormone-resistant or hormone ... Read Article